COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN COLOMBIA

被引：0
|
作者：
Lacey, M. [1 ]
Brouillette, M. [1 ]
Karpf, E. [2 ]
Lenhart, G. [1 ]
Barbeau, M. [3 ]
Russell, M. [1 ]
机构：
[1] Truven Hlth Analyt, Cambridge, MA USA
[2] Novartis Colombia, Bogota, Colombia
[3] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1218
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV72
引用
收藏
页码：A613 / A613
页数：1
相关论文
共 50 条
  • [41] Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review
    Proudfoot, Clare
    Gautam, Raju
    Cristino, Joaquim
    Agrawal, Rumjhum
    Thakur, Lalit
    Tolley, Keith
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (03): : 453 - 467
  • [42] Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction RESPONSE
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    ANNALS OF INTERNAL MEDICINE, 2017, 166 (08) : 607 - 608
  • [43] Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review
    Clare Proudfoot
    Raju Gautam
    Joaquim Cristino
    Rumjhum Agrawal
    Lalit Thakur
    Keith Tolley
    The European Journal of Health Economics, 2023, 24 : 453 - 467
  • [44] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction With a Recent Worsening Heart Failure Event
    Dixit, Neal
    Truong, Katie
    Ziaeian, Boback
    Fonarow, Gregg C.
    CIRCULATION, 2023, 148
  • [45] Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context
    D'Angiolella, Lucia S.
    Cortesi, Paolo A.
    Pitotti, Claudia
    Ritrovato, Daniela
    Mantovani, Lorenzo G.
    Senni, Michele
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (11) : 1551 - 1553
  • [46] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN GERMANY: APPLYING THE EFFICIENCY THRESHOLD
    Van der Pol, S.
    Postma, M. J.
    VALUE IN HEALTH, 2018, 21 : S6 - S6
  • [47] Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier
    van der Pol, Simon
    de Jong, Lisa A.
    Vemer, Pepijn
    Jansen, Danielle E. M. C.
    Postma, Maarten J.
    VALUE IN HEALTH, 2019, 22 (10) : 1119 - 1127
  • [48] Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System
    Wang, Zhe
    Lou, Yake
    Wang, Qi
    Sun, Min
    Li, Xiaonan
    Wang, Yinghui
    Wang, Yuehui
    CLINICAL DRUG INVESTIGATION, 2023, 43 (04) : 265 - 275
  • [49] Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System
    Zhe Wang
    Yake Lou
    Qi Wang
    Min Sun
    Xiaonan Li
    Yinghui Wang
    Yuehui Wang
    Clinical Drug Investigation, 2023, 43 : 265 - 275
  • [50] Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis
    Zaca, Valerio
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2018, 19 (10) : 597 - 605
12345